US Insurers Out of Step With IBD Treatment Guidelines US Insurers Out of Step With IBD Treatment Guidelines
Most US insurance companies require patients to fail conventional therapies for Crohn ' s disease and ulcerative colitis before they will cover a biologic agent, contrary to treatment guidelines.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - March 14, 2024 Category: Gastroenterology Tags: Gastroenterology Source Type: news

Sun Pharma recalls around 55k bottles of generic medication in US
Sun Pharma is recalling approximately 55,000 bottles of a generic medication used to treat bowel disease in the US market. The recall is due to "Failed Dissolution Specifications," according to the US Food & Drug Administration (USFDA). The affected Mesalamine extended-release capsules were manufactured at Sun Pharma's Mohali plant and distributed in the US by Sun Pharmaceutical Industries Inc. Mesalamine capsules are indicated for treating mild to moderate ulcerative colitis. The US generic drug market was valued at around USD 115.2 billion in 2019, with Sun Pharma being a major player in the market. (Source: The Econ...
Source: The Economic Times Healthcare and Biotech News - March 8, 2024 Category: Pharmaceuticals Source Type: news

Top-Down Treatment Superior for Crohn Disease
TUESDAY, March 5, 2024 -- Top-down treatment for Crohn disease (combination infliximab plus immunomodulator) achieves substantially better outcomes than accelerated step-up treatment, according to a study published online Feb. 22 in The Lancet... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 5, 2024 Category: Pharmaceuticals Source Type: news

Vedolizumab Shows Greater Persistence Than Tofacitinib in UC Vedolizumab Shows Greater Persistence Than Tofacitinib in UC
Vedolizumab had greater treatment persistence than tofacitinib in a retrospective study of patients with ulcerative colitis (UC) who were previously bio-naive.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - February 28, 2024 Category: Gastroenterology Tags: Gastroenterology Source Type: news

Novel Biotherapeutic to Be Tested in Ulcerative Colitis Novel Biotherapeutic to Be Tested in Ulcerative Colitis
An investigational combination of eight strains of bacteria known collectively as MB310 — a live biotherapeutic product — is due to start its first clinical trial in ulcerative colitis.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - February 26, 2024 Category: Gastroenterology Tags: Gastroenterology Source Type: news

Risankizumab Beats Ustekinumab for Previously Treated Crohn's
(MedPage Today) -- Risankizumab (Skyrizi) resulted in more clinical remissions compared with ustekinumab (Stelara) in adults with moderate to severe Crohn's disease who had failed at least one previous tumor necrosis factor (TNF) inhibitor, the... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - February 26, 2024 Category: Gastroenterology Source Type: news

AI-Identified Vascular Healing Can Predict Relapse in UC AI-Identified Vascular Healing Can Predict Relapse in UC
An AI-assisted image-enhanced endoscopy system accurately assessed vascular healing and predicted clinical relapse in patients with ulcerative colitis.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - February 26, 2024 Category: Gastroenterology Tags: Gastroenterology Source Type: news

Top-Down Treatment Superior to Step-Up Approach for Crohn's Disease
(MedPage Today) -- Early and aggressive immunosuppressive therapy with tumor necrosis factor (TNF) inhibitors significantly outperformed conventional therapy for patients with newly diagnosed Crohn's disease and should become the standard for most... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - February 26, 2024 Category: Gastroenterology Source Type: news

Treating Crohn's Sooner, More Aggressively Greatly Improves Outcomes: Study
MONDAY, Feb. 26, 2024 -- In a finding that suggests sooner is better than later, a new trial shows that giving advanced treatment early to Crohn ’s patients can dramatically improve their gut health.About 80% of those who got therapy with an... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - February 26, 2024 Category: General Medicine Source Type: news

New England Journal of Medicine publishes Phase III data showing Xolair significantly reduced allergic reactions across multiple foods in people with food allergies
Detailed results from the NIH-sponsored Phase III OUtMATCH study showed treatment with Xolair increased the amount of peanuts, tree nuts, egg, milk and wheat that people as young as 1 year consumed without an allergic reactionThe U.S. FDA recently approved Xolair as the first and only medicine for children and adults with one or more food allergiesAllergic reactions can be life-threatening and it is estimated that food-related anaphylaxis results in 30,000 medical events treated in emergency rooms in the U.S. each year1-3Basel, 25 February 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today data from Stage 1 of the N...
Source: Roche Investor Update - February 25, 2024 Category: Pharmaceuticals Source Type: news

New England Journal of Medicine publishes Phase III data showing Xolair significantly reduced allergic reactions across multiple foods in people with food allergies
Detailed results from the NIH-sponsored Phase III OUtMATCH study showed treatment with Xolair increased the amount of peanuts, tree nuts, egg, milk and wheat that people as young as 1 year consumed without an allergic reactionThe U.S. FDA recently approved Xolair as the first and only medicine for children and adults with one or more food allergiesAllergic reactions can be life-threatening and it is estimated that food-related anaphylaxis results in 30,000 medical events treated in emergency rooms in the U.S. each year1-3Basel, 25 February 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today data from Stage 1 of the N...
Source: Roche Media News - February 25, 2024 Category: Pharmaceuticals Source Type: news

Risankizumab in CD: Outcomes Remain Stable up to 3 Years Risankizumab in CD: Outcomes Remain Stable up to 3 Years
Long-term data show clinical remission and endoscopic response rates are maintained and even improve over time in patients with moderate to severe Crohn ' s disease, according to a new study.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - February 24, 2024 Category: Drugs & Pharmacology Tags: Gastroenterology Source Type: news

European Commission approves Pfizer & #039;s VELSIPITY ® for patients with moderately to severely Active ulcerative colitis
Pfizer Inc. (NYSE: PFE) announced that the European Commission (EC) has granted marketing authorization for VELSIPITY® (etrasimod) in the European Union to treat patients 16 years of age and older with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy, or a biological agent. (Source: World Pharma News)
Source: World Pharma News - February 23, 2024 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

Capsule Endoscopy –Guided Treatment Reduces Flares in Crohn's Capsule Endoscopy –Guided Treatment Reduces Flares in Crohn's
Patients with Crohn ' s disease who are considered high-risk as determined by capsule endoscopy but are in clinical remission benefit from a treat-to-target strategy, a new study shows.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - February 23, 2024 Category: Gastroenterology Tags: Gastroenterology Source Type: news

A Snapshot of Ulcerative Colitis: Part III A Snapshot of Ulcerative Colitis: Part III
Advanced practice nurse Kim Kearns illustrates the importance of ulcerative colitis disease control through a hypothetical patient case. Watch to learn more!Medscape Medical Affairs (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 20, 2024 Category: Consumer Health News Tags: None Virtual Symposium Source Type: news